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A B S T R A C T
Several neurodegenerative disorders, namely Parkinson’s disease dementia, dementia with Lewy bodies, and
Alzheimer’s disease, share common pathophysiological features, such as (1) cognitive deficits, (2) glutamatergic
hyperactivity-related excitotoxicity, and (3) deposition of α-synuclein (α-syn) and β-amyloid (Aβ). Ceftriaxone
(CEF) is a well-tested and safe drug that has been used as an antibiotic for several decades. Recent studies have
demonstrated the following effects of CEF: (1) increasing glutamate transporter-1 expression and glutamate
reuptake and suppressing excitotoxicity, (2) binding well with α-syn and inhibition of α-syn polymerization, (3)
modulating expression of genes related to Aβ metabolism, and (4) enhancing neurogenesis and recovery of
neuronal density. In addition, our data revealed that CEF ameliorates seizure and abnormal neuronal firing in the
brain. These results suggest the potential of CEF in treating neuronal disorders. This paper addresses the effects
and pharmacology of CEF.
1. Introduction to ceftriaxone (CEF)
CEF is a cephalosporin antibiotic approved for clinical use by the
FDA in 1984 as a broad-spectrum antibiotic for infections such as
pneumonia [1], bacterial meningitis [2], and gonorrhea [3]. Because
CEF has long been used clinically, its safety has been demonstrated
[4,5]. Recently, neuronal protective effects of CEF were observed in
animal models of neurodegenerative disorders, where CEF prevents
cognitive and motor deficits; inhibits dopaminergic (DAergic) degen-
eration in the striatum and substantia nigra pars compacta (SNc);
ameliorates cell loss in the hippocampus; restores neuronal density and
activity in the striatum, SNc, and hippocampus; and increases neuro-
genesis in the substantia nigra and hippocampal dentate gyrus (DG).
Increased glutamate reuptake through enhanced glutamate transporter-
1 (GLT-1) expression, elevation of neurogenesis, and regulation of
neuronal electrical activity may underlie the CEF-mediated neuronal
and behavioral protections. The results support the use of CEF in pa-
tients with neuronal disorders.
Several neurological studies of CEF were inspired by a ground-
breaking finding reported by Rothstein et al., who screened antibiotics
with the ß-lactam structure from 1040 FDA-approved drugs and ob-
served that CEF is able to promote transcription of the GLT-1 gene and
to increase GLT-1 protein levels in astrocytes. CEF enhanced glutamate
reuptake, reduced excitotoxicity, exhibited neuronal protection in
ischemia, and improves motor function in an animal model of amyo-
trophic lateral sclerosis (ALS) [6]. Activation of the GLT-1 promotor,
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through the transcriptional nuclear factor kappa B (NFκB) pathway,
was observed 48 h after CEF treatment, which maintained for at least 7
days [6]. After 5 days of CEF (200mg/kg/day, intraperitoneal injection
[IP]) treatment, GLT-1 protein levels increased three-fold compared
with controls in the hippocampus and spinal cord. The increased GLT-1
levels are biochemically active because reuptake of L-[3H]glutamate in
the cerebral cortex and hippocampus was increased [6]. Further ana-
lyses have determined that the fifty percent effective concentration
(EC50) of CEF for increasing GLT-1 expression was 3.5 μM, which is an
attainable level (0.36mM) of CEF in the central nervous system when
CEF is used for treating meningitis [7,8]. Rothstein and his colleagues’
research is indeed epoch-making. The effects of CEF, promoting GLT-1
expression, increasing glutamate reuptake, and inhibiting neurode-
generation, are quite different from what we known of CEF as an an-
tibiotic. We review the effects of and conclude the mechanism of CEF in
the paper.
2. CEF prevents behavioral and neuronal deficits in the rat model
of Parkinson’s disease dementia (PDD)
Several neurological disorders are associated with excessive gluta-
mate levels and deficits of GLT-1 expression [9,10]. Functional inter-
actions between the glutamatergic and dopaminergic (DAergic) systems
in the brain regulate motor and cognitive functions. DAergic degen-
eration causes parkinsonism [11], and atrophy in the hippocampal CA1
area results in anterograde amnesia [12]. Similarly, cell loss in the
hippocampal CA1 area has been observed to be accompanied by cog-
nitive deficits in a rat model of PDD [13], because neurogenesis in the
hippocampal DG is involved in learning and memory. The hippocampus
and the nigrostriatal DAergic system are rich in glutamatergic synapses
and are vulnerable to excitotoxic damage; therefore, excessive gluta-
mate release and excitotoxicity in these regions may lead to brain da-
mage and memory and cognition impairments in patients with Par-
kinson’s disease (PD) [14]. Thus, regulation of glutamatergic
transmission by enhancing GLT-1 expression could be an ideal phar-
macological target to prevent neuronal death and cognitive deficits
caused by glutamate excitotoxicity [6,15].
CEF produces a beneficial effect in the PD rat model by regulating
glutamatergic activity. In the 1-methyl-4-phenyl-1,2,3,6-tetra-
hydropyridine (MPTP)-induced PD rat model, decreased GLT-1 ex-
pression in astrocytes was observed [13]. CEF treatment (100 or
200mg/kg/day, IP) significantly increased GLT-1 expression in astro-
cyte in the striatum and hippocampus in both sham-operated and
MPTP-lesioned rats, irrespective of dose used or whether treatment was
started 5 days before or 3 days after the MPTP lesioning [13]. CEF
promoted nuclear translocation of p65 and increased the binding of
NFκB to the GLT-1 promoter, thus enhancing GLT-1 expression [16].
MPTP lesioning is widely used to induce PD in animal models, because
it destroys DAergic neurons in the SNc leading to a loss of DAergic
terminals in the striatum. The lesioning also decreases the density of
pyramidal neurons in the hippocampal CA1 and DG areas and reduces
GLT-1 expression in astrocytes in the striatum and hippocampus
[13,14]. In addition, MPTP lesioning causes glutamatergic hyper-
activity that contributes to excitotoxicity, neurodegeneration, motor
function deficits, and impairments in working memory and object re-
cognition, which mimic the pathophysiology of PDD. CEF increased
GLT-1 expression, enhanced removal of released glutamate from the
synapse, and ameliorated glutamate excitotoxicity [6]. By contrast,
intranigral injection of dihydrokainate (DHK), an antagonist of the GLT-
1, reversed the protective effects of CEF [17]. Most brain cells express
glutamate receptors and are thereby influenced by extracellular gluta-
mate. The brain cells have powerful uptake systems that constantly
remove glutamate from the extracellular fluid and thereby limit re-
ceptor activation. Although both neurons and astrocytes express glu-
tamate transporters, the GLT-1 in the astrocyte accounts for around
95% of the total glutamate reuptake activity [18]. Thus, CEF-induced
glutamatergic regulation may mainly through the GLT-1 expression in
the astrocyte. Furthermore, ischemia increased glutamate release in the
cortex and hippocampus, which was suppressed by CEF pretreatment
[19].
Immunohistochemical evaluation indicated that CEF treatment
significantly inhibited the MPTP-induced decrease of density of DAergic
terminals and neurons in the striatum and SNc, respectively.
Furthermore, the loss of pyramidal cells in the hippocampal CA1, CA3,
and DG areas caused by MPTP was suppressed by CEF treatment
[14,20]. The number of neural precursor cells and proliferating cells
was observed to be reduced in postmortem brains of patients with PD,
indicating an impairment of neurogenesis [21]. This was also observed
in a PD rat model [14,22]. Moreover, we observed that CEF increased
the number of newborn cells in the SNr and in the hippocampal DG in
the MPTP-induced rat model of PDD [22]. These newborn cells may
eventually migrate to the SNc and CA1, respectively, which may ex-
plain the recovery of neuronal density in the SNc and hippocampus
after CEF treatment. DAergic deficits were considered to be the main
pathological cause of PD, which inspired the development of L-dopa and
also supported the effects of this drug. However, patients with PD also
develop dementia, PDD, and the cognitive deficits are associated with
their hippocampal atrophy. L-dopa does not inhibit neurodegeneration
in the hippocampus and certainly not block or treat dementia in PD
patients. In addition to DAergic degeneration, the hippocampal cell loss
mediates PDD. Glutamate-induced excitotoxicity underlie neuronal
death in the above two regions. CEF enhances GLT-1 expression, cleans
up excess glutamate, prevents excitotoxicity and neurodegeneration,
increases new born cells in the brain regions, and improves symptoms
of PDD.
CEF affects not only glutamatergic transmission but also the neu-
ronal activity of the brain. The activity of the mitochondrial enzyme,
cytochrome oxidase, is used to evaluate metabolic activity of the
neuron. MPTP lesioning significantly increased levels of cytochrome
oxidase in the subthalamic nucleus (STN). However, this increase was
not seen after receiving CEF treatment [13,14]. The suppression of STN
hyperactivity by CEF was also observed when measuring neuronal ac-
tivity by using manganese-enhanced magnetic resonance imaging
(MEMRI) in vivo [14]. However, MPTP lesioning resulted in decreased
neuronal activity in the striatum, cortex, and hippocampus, which was
prevented by the treatment with CEF. Furthermore, positive correla-
tions between neuronal activity and density of neurons in the SNc and
hippocampus were observed after CEF treatment [14]. Similarly and
even more interestingly, we recently determined that CEF treatment
suppressed burst discharges in the STN of a PD rat model (Fig. 1).
Moreover, Bellesi et al. reported that 8 days of CEF (200mg/kg/day)
treatment resulted in a delayed reduction in electroencephalogram
(EEG) theta power (7–9 Hz) in both frontal and parietal areas [23].
Theta oscillations are observed in several areas of the brain, such as the
hippocampus and cortical and subcortical structures, which are corre-
lated with long-term potentiation (LTP) [45] and synaptic plasticity
[46]. In addition, reduction of theta power reflects lower synchroni-
zation of neuronal activity, which may stabilize electrophysiological
activity of the brain and may thus be involved in suppression of burst
firing and seizures. Changing stimulation frequency from 0.1 Hz to 1 Hz
for 30 s caused an increase in field excitatory postsynaptic potentials
(fEPSP) amplitude, which was reduced in CEF-treated rats. Further-
more, CEF suppressed LTP and long-term depression (LTD) at synapses
of CA3 mossy fibers [24]. Because LTP and LTD are involved in neu-
ronal plasticity, these results suggest a novel mechanism by which CEF
regulates neuronal and behavioral functions. It needs further studies to
elucidate the mechanism by which CEF affects EEG and LTP/LTD.
3. CEF may be useful to treat α-synuclein (α-syn)- and β-amyloid
(Aβ)-related neuronal disorders
Dementia with Lewy bodies (DLB), PDD, and Alzheimer’s disease
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(AD) are different disorders, but they exhibit common pathophysiolo-
gical changes, where α-synucleinopathies and Aβ cause neuroin-
flammation and neurodegeneration. Therefore, these changes have
been the center of focus in understanding the etiology of these neuro-
degenerative disorders [25], since elimination of α-syn and Aβ may
prevent these disorders.
DLB was initially identified as a dementia syndrome with Lewy
body pathology. Neurocognitive syndromes occur in patients with DLB
when Lewy bodies invade the limbic system and associative neocortices
[26]. Cellular pathologies of Lewy bodies, including α-syn and Aβ de-
position, are hallmarks of DLB [27]. In contrast to DLB, which is
characterized by a dominant dementia syndrome followed by parkin-
sonism, PD is a dominant movement disorder. PD patients also display a
dementia syndrome with an initial diagnosis of parkinsonism for more
than 1 year, where the cognitive symptoms are thought to occur when
Lewy bodies are prevalent in the brain [26]. In addition, recent post-
mortem studies suggest that as many as one half of AD patients has α-
syn aggregation in the brain [28,29].
The pathophysiology of DLB is related to the aggregation of Lewy
bodies and Lewy neurites that are formed by α-syn accumulation
[30,31], resulting in neurotoxicity and cell loss in the brain [32–34]. In
addition to α-syn accumulation, the deposition of extracellular Aβ is
also observed in the brain of up to eighty percent of DLB patients [35].
Aβ not only exacerbates neuronal toxicity of α-syn but also prolongs the
extracellular lifetime of glutamate in the synapse by reducing GLT-1
expression in astrocytes [36]. We reported a method of injection of Aβ
and viral vectors with the SNCA gene into the brain to induce the DLB
rat model [37]. The DLB rats showed a high level of α-syn accumulation
in the hippocampal DG area and a lower density of pyramidal neurons
in the hippocampal CA1. CEF (100mg/kg/day, IP) treatment corrected
the aforementioned neuronal changes and reduced α-syn accumulation,
indicating that CEF is a potential agent for the treatment of DLB [38].
Neuronal α-syn inclusions and pathological α-syn transmission play a
leading role in the initiation of Parkinson-like neurodegeneration. A
recent in vitro study demonstrated that CEF binds to α-syn and blocks its
polymerization [39]. The binding may underlie the effects of CEF on
reducing α-syn accumulation and restoring neuronal density and ac-
tivity in the brain of DLB rats.
Chronic CEF (100mg/kg/day, IP) administration for 36 days re-
duced cognitive deficits and ameliorated neurodegenerative changes in
the hippocampus in OXYS rats, a model of sporadic AD [40]. The
“amyloid cascade hypothesis” proposes that Aβ plays a critical role in
the pathogenesis of AD. Modulating the expression of enzymes involved
in the metabolism of Aβ has been suggested as an effective strategy for
the prevention and therapy of AD. Tikhonova et al. recently determined
that CEF (100mg/kg/day, IP) treatment for 36 days affected expression
of mRNA, which is involved in Aβ metabolism. CEF diminished the
Bace1 mRNA level but augmented Ide, Mme, and Ece1 mRNA levels in
the brain of OXYS rats. The Bace1 is involved in the increase of Aβ
levels but Ide, Mme, and Ece1 are involved in decrease of Aβ levels.
Moreover, CEF treatment increased Epo mRNA levels, which are
associated with erythropoietin (EPO) expression, neurodevelopment,
neurogenesis, and neuroprotection [41]. This is consistent with our
previous data illustrating a synergistic effect of combined treatment
with CEF and exogenous EPO on neuroprotection as well as cognitive
improvements in the MPTP-induced PDD rat model [42]. Accumulation
of α-syn and Aβ plays an important role in the pathophysiology of DLB,
PDD, and AD. Aβ triggers oxidative stress, which stimulates α-syn ag-
gregation [43] and deteriorates neurotoxicity [44]. Inhibiting α-syn
accumulation, enhancing antioxidant activity [45,46], and regulation
of Aβ metabolism, decreasing production and increasing degradation
[41], may underlie neuronal and behavioral protections of CEF in the
neurological diseases. Further studies are needed to provide support for
the CEF effects on AD and gene regulations.
4. Beneficial effects of CEF on movement disorders
Alexander’s disease is a genetic disease characterized by progressive
motor deterioration with no cure. A case report indicated that admin-
istration of CEF reversed the progression of neurodegeneration in a
patient with adult-onset Alexander's disease and substantially improved
her quality of life. Before CEF therapy, in a 2-year period, gait ataxia
and dysarthria worsened from mild to marked; palatal myoclonus
spread from the soft palate to lower facial muscles; and the patient
complained of oscillopsia. After 4 years of CEF therapy (2 g/day, IV, for
3 weeks monthly during the initial 4 months, then for 15 days
monthly), gait ataxia and dysarthria were improved, from mild to
marked at clinical rating scales. The palatal myoclonus was no longer
detectable, and the patient did not complain of oscillopsia and reported
a progressively better quality of life [47] (Table 1).
A decrease in GLT1 expression has been reported in motor cortex
and spinal cord of patients with ALS [48]. CEF (200mg/kg/day, IP)
treatment for 7 days increased muscle grip and reduced the loss of body
weight in the animal model of ALS (G93 A SOD1 mice). Two weeks of
CEF treatment reduced the death of spinal motor neurons and the
gliosis of nerve tissue and improved the survival rate of the ALS animals
[6]. Moreover, ALS Functional Rating Scale – Revised (ALSFRS-R)
scores declined more slowly in patients with ALS who received CEF
treatment (4 g/day, through a central venous catheter for 6 months)
than in those on placebo in a large-scale clinical trial involving 514 ALS
patients [49]. Notably, restoration of neuronal connections between
CNS and PNS may also contribute to CEF effects because increased
numbers of corticospinal tract axons and restoration of hind limb motor
function were observed after 7 days of CEF (200mg/kg/day, IP)
treatment in rats with spinal cord injuries [50].
5. Beneficial effects of CEF on ischemia, pain, and seizure
Disruption of homeostasis of glutamatergic neurotransmission,
causing excitotoxicity and cell death, plays a pathophysiological role in
cerebral ischemia. Middle cerebral artery occlusion increased glutamate
release and suppressed astrocytic GLT-1 expression in the frontal cortex
Fig. 1. Effects of ceftriaxone (CEF) on burst discharges in the
subthalamic nucleus of a Parkinson’s disease (PD) rat model. CEF
(200mg/kg/day, IP) was administered for 2 weeks in the 6-hy-
droxydopamine-induced PD rat model. (A) The sham+ saline
group demonstrated a spike firing pattern. (B) Burst discharges
were observed in PD rats. (C) Burst discharges were suppressed by
CEF treatment. (D) The CEF effect was blocked by dihydrokainate
(DHK) (0.14mg/kg/day, IP) treatment. (E) Quantitative results.
The data are expressed as the mean ± SEM. *** P < 0.001
compared with the Sham+saline group, ### P < 0.001, com-
pared with the PD+saline group. The experiment and the PD rat
model were induced under the approval by the Animal Care
Committee of Chung Shan Medical University (IACUC approval
No. 1455) and the STN electrical activity was recorded as in our
previous reports [66,67].
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and hippocampus. CEF (200mg/kg/day, IP) pretreatment suppressed
these changes in rats, where enhanced GLT-1 mRNA and protein levels
were observed after 3 and 5 days of treatment, respectively [19]. CEF-
pretreated rats displayed a reduction in brain infarct volume, compared
with vehicle-pretreated animals at 24 h post-ischemia; additionally, the
rats showed better functional recovery in a limb placing test at day 1 to
week 5 after the ischemia [51]. Lower doses of CEF (20mg/kg/day)
reduced infarct volumes to a lesser degree. However, CEF administra-
tion at 30min after ischemia produced no significant reduction in in-
farct volume, indicating the vital role of GLT-1 expression. CEF up-
regulates GLT-1 expression and restores glutamate homeostasis, which
may promote brain tolerance to ischemia; therefore, CEF may be a
compelling candidate for the development of new therapies to combat
brain ischemia.
Hyper-glutamatergic activity is associated with chronic pain. CEF
alleviated mechanical allodynia and thermal hyperalgesia in a chronic
constriction injury (CCI) rat model of neuropathic pain. Daily dosing of
CEF (200, 300, and 400mg/kg) reached the same withdrawal threshold
levels as before the CCI surgery, after 18, 12, and 7 days of treatment,
respectively. This indicates that the dynamic effect of CEF depends not
only on dose, but also on the duration of administration [52]. Thus, it
seems that dose exposure above a certain threshold is necessary to
produce these effects. Higher doses not only induced larger effects, but
also sped up their appearance. Seven days of CEF pretreatment (in-
trathecal injection) attenuated the development of hyperalgesia and
allodynia in response to repeated morphine administration and pre-
vented associated astrocyte activation [15]. One week of administration
of CEF was successful to mitigate visceral nociception, which was
blocked by intrathecal delivery of selective GLT-1 antagonist DHK,
suggesting a spinal site of action [53].
Glutamatergic hyperactivity is involved in abnormal neuronal firing
and seizure. Our recent study demonstrated that CEF has protective
effects on epilepsy and associated cognitive deficits (Fig. 2). Systemic
administration of a sub-convulsive dose of pentylenetetrazole (PTZ)
(30mg/kg) every other day for 27 days (14 injections) increased
kindling progressively, led to generalized tonic-clonic seizures, and
caused impairments in motor coordination, cognitive function, and
oxidative defense in the cortex and subcortical region. CEF (100 and
200mg/kg) treatment significantly decreased the mean kindling score
and prevented the decline of cognitive function and oxidative defense
activity in the PTZ-induced seizure rats [54]. Similarly, CEF (200mg/
kg/day) pretreatment for 6 days provided considerable protective ef-
fects against PTZ-evoked generalized clonic and tonic convulsions and
convulsion-induced mortality [55]. CEF (200mg/kg/12 h) treatment
for 3 days, starting from the sixth dose of PTZ, significantly ameliorated
PTZ-induced convulsions and restored anti-oxidative activity in rats
[56]. Lower percentages of EEG spikes were associated with lowered
convulsion in CEF (200 and 400mg/kg)-treated rats [57]. Furthermore,
a noteworthy case report indicated that cefixime, a cephalosporin an-
tibiotic with similar structure with CEF, also produces an anti-seizure
effect. The case report featured a 9-year-old boy suffering from autism
and generalized tonic-clonic epilepsy who had taken medications
without favorable control of his epilepsy. When the patient took ce-
fixime 200mg/day to control diarrhea, the seizure episodes were dra-
matically decreased 3 to 5 days after starting the treatment, though
there was no change in his anti-epileptic medication regimen [58].
CEF may treat different symptoms (such as motor dysfunction,
cognitive impairment, stroke neuronal death, pain, and seizure) of
different diseases through some common mechanisms because these
diseases have some common pathophysiological features. CEF may be a
non-specific mechanism drug that can simultaneously suppress the
common features the neurological diseases, thus treating various
symptoms of different diseases and showing multifunctional effects.
6. Mechanisms of CEF effects on neurological disorders
Although various neurodegenerative diseases have their main
causes, many of the diseases have some common pathophysiological
features, such as glutamatergic hyperactivity, excitotoxicity, oxidative
stress, neuroinflammation, and accumulation of harmful proteins. CEF
Table 1
Effects of ceftriaxone on neurological diseases.
Disease CEF effects References
PD/PDD CEF increased GLT-1 expression in astrocyte in the striatum and hippocampus and suppressed hyperactivation
of cytochrome oxidase in the STN in the MPTP-induced PD rat model.
[13] Hsu et al., 2015
CEF inhibited cell loss in the hippocampus and the DAergic system in the MPTP-induced PD rat model. [14] Weng et al., 2016
PD rats showed hyperactivity in the STN but decreased neuronal activity in the striatum, cortex, and
hippocampus, which were ameliorated by CEF treatment, measured by using MEMRI.
[20] Ho et al., 2014
CEF increased the number of newborn cells in the SNr and in the hippocampal DG in the MPTP-induced rat
model of PDD.
[22] Hsieh et al., 2017
CEF suppressed burst discharges in the STN of PD rat model. The present paper (Fig. 1)
α-Syn and Aβ-related
disorders
CEF corrected neuronal loss and reduced α-syn accumulation in the hippocampus in a DLB rat model. [38] Ho et al., 2018
CEF binds to α-syn and blocks its polymerization. [39] Ruzza et al., 2014
CEF reduced cognitive deficits and ameliorated neurodegenerative changes in the hippocampus in OXYS rats, a
model of sporadic AD.
[40] Tikhonova et al., 2017
In the OXYS AD rat model, CEF regulated gene expressions that are involved in Aβ metabolism and EPO levels. [41] Tikhonova et al. 2018
Movement disorders CEF improved gait ataxia, dysarthria, and myoclonus in a patient with Alexander’s disease. [47] Sechi et al., 2013
CEF reduced the death of spinal motor neurons and the gliosis of nerve tissue and improved the survival rate in
an ALS animal model.
[6] Rothstein et al., 2005
CEF slowed down the decline of motor function in patients with ALS, in a large-scale clinical trial. [49] Cudkowicz et al., 2014
Ischemia CEF restored changes of glutamate release and GLT-1 expression in the frontal cortex and hippocampus and
reduced brain infarct volume in ischemia rat model.
[19] Krzyzanowska et al., 2017
[51] Chu et al., 2007
Pain CEF alleviated allodynia and hyperalgesia and prevented astrocyte activation in rat models of neuropathic
pain, which is associated with spinal site of action.
[15] Ramos et al., 2010
[52] Frederiksen et al., 2017
[53] Lin et al., 2011
Seizure CEF decreased clonic and tonic convulsions, prevented the decline of cognitive function, enhanced oxidative
defense activity, and reduced mortality in the PTZ-induced seizure rats.
[54] Soni et al., 2015
[55] Jelenkovic et al., 2008
[56] Hussein et al., 2016
The present paper (Fig. 2)
Abbreviations: ceftriaxone (CEF), Parkinson’s disease dementia (PDD), glutamate transporter-1 (GLT-1), dopaminergic (DAergic), subthalamic nucleus (STN);
manganese-enhanced magnetic resonance imaging (MEMRI); α-synuclein (α-syn); β-amyloid (Aβ); Alzheimer’s disease (AD), erythropoietin (EPO); amyotrophic
lateral sclerosis (ALS); pentylenetetrazole (PTZ).
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exerts several pharmacological effects that inhibits the above patholo-
gical features and thus can ameliorate many different neurodegenera-
tive diseases and their symptoms. The above pathophysiological fea-
tures are involved in neurodegeneration and behavioral dysfunction
through downstream biochemical changes. Glutamatergic hyperactivity
causes excessive glutamate release; the glutamate activates N-methyl-D-
aspartate (NMDA) receptors and causes Ca2+ overload in the cells,
which leads to excitotoxicity and apoptosis. Ca2+ overload can lead to
mitochondrial dysfunction, neuronal hyperactivity, seizure, and a
consequence of cell death. Cell death induces neuroinflammation,
which increases oxidative stress and in turn worsens apoptosis. Aß in-
hibits GLT-1 expression and suppresses glutamate reuptake, leading to
high level of extracellular glutamate. Accumulation of α-syn facilitates
oxidative stress that gives rise to apoptosis and neuroinflammation. CEF
activates NF-κB and mediates expression of several proteins [59]. CEF-
induced increases of GLT-1 expression in the astrocyte enhances glu-
tamate reuptake and lowers extracellular glutamate [6]. CEF regulates
expression of genes related to Aß metabolism, reducing production but
increasing clearance of Aß [41]. CEF binds directly to the molecular of
α-syn, inhibiting α-syn polymerization and Lewy bodies accumulation
[39]. In addition, CEF increases levels of antioxidant enzymes (glu-
tathione and catalase) [45,46] and Bcl2 but decreases caspases 3 and 9.
These effects may mitigate oxidative sttress, apoptosis, and neuroin-
flammation [46]. Furthermore, CEF promotes levels of brain-derived
neurotrophic factor (BDNF) [17] and EPO mRNA [41], which may
suppress oxidative stress and be beneficial for neurogenesis as well as
neuronal survival. All the aboves are pharmacological effects of CEF,
which suppresses neurodegeneration and symptoms of neurological
disorders (Fig. 3).
7. Periodic administration of CEF
Because CEF has antibacterial activity, using it to treat chronic
diseases should not result in drug resistance induced by long-term use.
Basic studies have demonstrated that continuous long-term adminis-
tration of CEF is not necessary because periodic administration is suf-
ficient to produce neuronal and behavioral protections.
Activation of the GLT-1 promotor was observed 48 h after CEF
(100 μM) treatment in a cell culture [6]. CEF (200mg/kg/day, IP)-en-
hanced GLT-1 mRNA and protein expressions were observed after 3 and
5 days of treatment, respectively [51]. Seven days of intrathecal in-
jection with CEF enhanced spinal expression of GLT-1 in naïve rats,
which was not observed 7 days after the end of the treatment [15]. Five
days of pretreatment with CEF (200mg/kg/day, IP) prevented
ischemia-induced behavioral and brain damage [51]. In addition, 7
days of systemic injection of CEF (200mg/kg/day) increased GLT-1
expression in glia, enhanced glutamate reuptake, and displayed neu-
roprotection in a mouse model of ALS [6]. CEF-induced GLT-1 up-
regulation persisted for at least 4 days after the end of treatment and
returned to baseline 8 days after the end of treatment [6,60].
There is also a delayed emergence of behavioral and electro-
physiological (LTD and LTP) changes associated with CEF-induced GLT-
1 up-regulation, which can be observed after 8 days of CEF treatment.
This delay may indicate that synaptic modifications and functional
consequences of CEF require time to effect dynamic changes in neu-
ronal population and lead to behavioral changes [24]. CEF still main-
tains the same effect after 3 months of continuous treatment. These
results indicate that it takes time (e.g., 2–5 days) for CEF to produce its
relevant effects, that the effects remain for a period (e.g., 1 week), and
that CEF does not quickly develop tolerance [6].
Safety and human dose
CEF is safe and well tolerated. The potential toxicity of CEF (2 g/kg/
day) for long-term use has been assessed in SD rats that received CEF
administered subcutaneously once daily for 182 consecutive days in
order to investigate the delayed onset of any toxicity. No toxicologically
meaningful changes were observed. In addition, apart from the de-
crease in red blood cell count, no CEF-related changes in hematology,
coagulation, clinical chemistry, or urine parameters were observed [5].
For conducting clinical trials, data derived from animal models are
used to estimate the safe starting dose for human studies. Body surface
area (BSA)-based dose calculation is an appropriate method for dose
translation across species. For initial clinical trials in healthy adult
volunteers, Reagan-Shaw et al. suggested to obtain the human
equivalent doses (HED) using the following formula based on BSA
normalization of the animal dose [61]: HED (mg/kg) = rat dose (mg/
kg) × (rat km factor/human km factor), where the rat km factor is 6
and the human km factor is 37.
The dose of CEF used to treat bacterial infections and meningitis has
been reported to be 2 g/day for 2 months, with no side effects in pa-
tients [62]. The recommended CEF routine use for human adults is
1–4 g/day for seven to 10 days. The effective daily dose of CEF for
treating animals in models of neurodegenerative disorder was 200mg/
kg, with no adverse side effects [20,63,64]. Lower doses of CEF (20 and
Fig. 2. Effects of ceftriaxone (CEF) on seizures and cognitive function in a
pentylenetetrazol (PTZ)-induced seizure rat model. PTZ (35mg/kg, IP) was
administered every other day; CEF (100mg/kg, IP) was administered daily, 6 h
after PTZ injection on the treatment day. Seizure intensity was measured with
Racine’s convulsion scores [56]. (A) CEF significantly reduced seizure scores
starting from day 7. (B) Object recognition was impaired in PTZ-rats, which was
prevented in rats receiving CEF treatment, as indicated by a higher percentage
of time exploring the new object. The experiment and the seizure rat model
were induced under the approval by the Animal Care Committee of Chung Shan
Medical University (IACUC approval No. 2083). The object recognition test was
performed on days 25 to 27 as in our previous report [22].
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100mg/kg/day) displayed a similar protective effect but to a lesser
degree [51]. Notably, CEF at a very low dose of 5mg/kg/day also de-
monstrated neuroprotection and behavioral benefits [42]. Based on the
dose translation formula [61], the neuroprotective dose (200mg/kg/
day) of CEF in the animal study can be translated to the adult human
(body weight= 70 kg) equivalent dose as 2.268 g/day, which is similar
to the dosage of CEF when used as an antibiotic (1–4 g/day). Because
the up-regulation of GLT-1 expression by CEF is short-lived [6], peri-
odic long-term treatment of CEF will be feasible, in which administra-
tion of CEF every other week is suggested. Five days of CEF treatment in
the treatment week are necessary to potentiate and prolong its bene-
ficial effects. Using the aforementioned dose (sterilizing dose) and
periodic administration (1-week administration and 1-week drug
holiday), bacterial resistance can be avoided, although CEF displays
antibacterial activity. An international, multi-center phase II clinical
trial to assess the efficacy and safety of CEF in patients with mild to
moderate PDD, in which CEF is administered periodically and con-
tinually, has been approved by the US FDA and is currently being
performed in Taiwan [65].
8. Conclusion
Several neurodegenerative diseases share common pathophysiolo-
gical features, such as (1) interaction of α-syn and Aβ to form Lewy
bodies and (2) glutamate-related neurotoxicity. Recent studies have
demonstrated that CEF prevents α-syn polymerization and accumula-
tion, inhibits Aβ production, accelerates its elimination, increases GLT-
1 expression, removes glutamate, reduces excitotoxicity, and enhances
neurogenesis. Electrophysiological, neurochemical, and in vivo MEMRI
studies suggest that CEF inhibits hyperactivity (e.g., in the STN) but
activates neural regions that would otherwise be underactive.
Experiments in animal models of neurodegenerative diseases (e.g.,
PDD, DLB, AD, ALS, and ischemia) have demonstrated that CEF
prevents neurodegeneration, promotes neurogenesis, restores neuronal
density, and improves motor and cognitive functions. In addition, CEF
demonstrates neurological and behavioral benefits in animal models of
epilepsy, pain, and spinal cord injury. CEF slows the progressive dete-
rioration of motor function in patients with ALS and with Alexander’s
disease and reduces seizure episodes. This evidence suggests that CEF
may have potential for the treatment of neurological diseases. Well-
controlled clinical trials are required to examine the effects in human
patients.
Based on the doses used in animal studies, it is estimated that the
HED of CEF is 1–2 g/day for a clinical trial. Because the action of CEF
involves the regulation of genes, the activation of promotors, and the
production of proteins, it takes several days to produce effects. Once the
effects are present, they last for approximately 1 week, so we suggest
that CEF should be administered periodically, every other week, and
chronically in the clinical trial.
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